CLINICAL TRIALS PROFILE FOR ANTITHROMBIN III (HUMAN)

All Clinical Trials for antithrombin iii (human)

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00174902 ↗	The Effect of Beta-Blockers and Aspirin on Hemostasis and Endothelial Function After Acute Mental Stress	Unknown status	Swiss National Science Foundation	Phase 1/Phase 2	2003-10-01	This randomized double-blinded controlled trial uses a factorial design to investigate whether application of beta-blockers (inderal 80 mg) or aspirin (100 mg) or a combination thereof has an effect on the activation of the hemostatic system, the platelets and the endothelium in response to acute mental stress. Specifically we test the hypothesis that inderal attenuates the activation of the hemostatic system as compared to placebo. The second hypothesis is that aspirin attenuates the activation of platelets as compared to placebo. Subjects will be randomly allocated to either of the four following study arms: placebo - inderal - aspirin - inderal plus aspirin. Subjects will receive the study medication for five days prior to the mental stress. The acute mental stress consists of a public speaking session of 10 min duration immediately followed by a mental arithmetic test of 5 min duration. Blood will be collected prior to the stress, immediately thereafter, at 45 min at at 1 hour and 45 min.
NCT00174902 ↗	The Effect of Beta-Blockers and Aspirin on Hemostasis and Endothelial Function After Acute Mental Stress	Unknown status	Swiss Federal Institute of Technology	Phase 1/Phase 2	2003-10-01	This randomized double-blinded controlled trial uses a factorial design to investigate whether application of beta-blockers (inderal 80 mg) or aspirin (100 mg) or a combination thereof has an effect on the activation of the hemostatic system, the platelets and the endothelium in response to acute mental stress. Specifically we test the hypothesis that inderal attenuates the activation of the hemostatic system as compared to placebo. The second hypothesis is that aspirin attenuates the activation of platelets as compared to placebo. Subjects will be randomly allocated to either of the four following study arms: placebo - inderal - aspirin - inderal plus aspirin. Subjects will receive the study medication for five days prior to the mental stress. The acute mental stress consists of a public speaking session of 10 min duration immediately followed by a mental arithmetic test of 5 min duration. Blood will be collected prior to the stress, immediately thereafter, at 45 min at at 1 hour and 45 min.
NCT00262054 ↗	Un-fractionated Heparin Versus Bivalirudin During Percutaneous Coronary Interventions (PCI) (ISAR-REACT-3)	Completed	Deutsches Herzzentrum Muenchen	Phase 4	2005-11-01	The purpose of this study is to determine whether bivalirudin given during PCI is associated with better outcomes compared to un-fractionated heparin.
NCT00293501 ↗	Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery	Unknown status	National Cancer Institute (NCI)	Phase 1/Phase 2	2005-12-01	RATIONALE: Tinzaparin may stop the growth of kidney cancer by blocking blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects of tinzaparin and to see how well it works in treating patients with metastatic kidney cancer that cannot be removed by surgery.
NCT00293501 ↗	Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery	Unknown status	University of Vermont	Phase 1/Phase 2	2005-12-01	RATIONALE: Tinzaparin may stop the growth of kidney cancer by blocking blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects of tinzaparin and to see how well it works in treating patients with metastatic kidney cancer that cannot be removed by surgery.
NCT00319228 ↗	Safety, Pharmacokinetics and Efficacy of an AT-III Concentrate.	Active, not recruiting	Grifols Biologicals Inc.	Phase 2/Phase 3	2006-01-01	To assess the safety, pharmacokinetics and efficacy of a plasma-derived AT-III concentrate in the treatment of subjects with congenital AT-III deficiency.

Clinical Trial Conditions for antithrombin iii (human)

Condition Name

Condition Name for antithrombin iii (human)
Intervention	Trials
Venous Thromboembolism	5
Cardiopulmonary Bypass	3
Extracorporeal Membrane Oxygenation Complication	3
Antithrombin III Deficiency	3

Condition MeSH

Condition MeSH for antithrombin iii (human)
Intervention	Trials
Antithrombin III Deficiency	8
Venous Thrombosis	8
Thrombosis	8
Thromboembolism	5

Clinical Trial Locations for antithrombin iii (human)

Trials by Country

Trials by Country for antithrombin iii (human)
Location	Trials
United States	63
Italy	14
Germany	7
United Kingdom	6
China	6

Trials by US State

Trials by US State for antithrombin iii (human)
Location	Trials
New York	5
Pennsylvania	4
North Carolina	4
Florida	4
Arizona	4

Clinical Trial Progress for antithrombin iii (human)

Clinical Trial Phase

Clinical Trial Phase for antithrombin iii (human)
Clinical Trial Phase	Trials
Phase 4	27
Phase 3	13
Phase 2/Phase 3	4

Clinical Trial Status

Clinical Trial Status for antithrombin iii (human)
Clinical Trial Phase	Trials
Completed	36
Unknown status	13
Recruiting	11

Clinical Trial Sponsors for antithrombin iii (human)

Sponsor Name

Sponsor Name for antithrombin iii (human)
Sponsor	Trials
rEVO Biologics	4
National Cancer Institute (NCI)	3
University of Vermont	3

Sponsor Type

Sponsor Type for antithrombin iii (human)
Sponsor	Trials
Other	116
Industry	38
NIH	3